RESUMEN
Introduction: Adjuvant Online! [AOL] is used extensively by oncologists in Iran to treat patients with breast cancer; however, it has never been validated for use in Iran, and its predictions might not be applicable to Iranian patients. The aim of this study was to evaluate the usefulness of this program in predicting the outcomes of Iranian patients with breast cancer
Patients and methods: 368 patients who were treated between 1997 and 2010 at Jorjani Cancer Center entered the study. Data for each patient, including tumor size, number of positive nodes, tumor grade, ER status, and adjuvant systemic therapy, were entered into the AOL program [version 8.0], and the calculated disease free survival [DFS] was compared with the observed one. Analyses were performed using Cox regression modeling and SPSS 17.0 software, and P values < 0.05 were considered significant
Results: Observed disease free survival [DFS] in our study was 72 months, while the calculated DFS by AOL was 68 months. In all subgroups of AOL, calculated DFS was less than observed DFS except for patients receiving Tamoxifen + Aromatase Inhibitors + Ovarian Ablation hormone therapy, for whom the calculated DFS was 2 percent more than the observed one
Conclusion: AOL underestimated overall survival and disease free survival rates in Iranian patients with breast cancer, which in our opinion was mainly due to the shorter period of follow-up in our study. Although AOL is widely used by Iranian oncologists, we believe that developing an Iranian version of a prediction tool would better predict the prognosis of our patients
RESUMEN
With regard to the increasing prevalence and mortality rate of prostate cancer and several related reports studying the role of promoter Hypermethylation of RARB and p16 in predicting the prognosis, this research is carried out on 3 groups of subjects with; poor prognostic factors [case], good prognostic factors [control-2] and healthy person [control-1], at three general hospitals of Imam Hossein, Modarres and Labbafineyhad, between 2007-2009. The research has case-control Design. All three groups of participants [21 subjects in each group] were analyzed for hypermethylation of RARB- p16. All groups were matched for age, tumor stage, grade and PSA. The technique was methylation specific polymerase chain reaction [MSPCR]. In control-1, no methylation of RARB were observed. In control-2, RARB was positive in 33%. In case group, the RARB was positive for 71.4%. For control 2 and case groups, the RAR positivity was higher than control-1 [P< 0.001], however, that of case group was higher than control-2[p<0.02]. In healthy persons p16 were negative. For good prognosis group p16 were positive in 19%, while for poor prognosis one, p16 were positive in 47.6%. p16 hypermethylation was higher in case and control-2 groups [P<0.001]. Nevertheless, for case group this was higher than control-2 [P< 0.01].:Hypermethylation of promotor RARB and p16 would be a good prognostic factor for early detection and prognosis of prostatic cancer